Catalyst Pharmaceuticals, Inc. (CPRX)
After hours:
| Previous Close | 15.92 |
| Open | 16.01 |
| Bid | 15.86 x 400 |
| Ask | 15.91 x 400 |
| Day's Range | 15.80 - 16.07 |
| 52 Week Range | 11.09 - 17.50 |
| Volume | |
| Avg. Volume | 1,323,890 |
| Market Cap | 1.88B |
| Beta (5Y Monthly) | 0.89 |
| PE Ratio (TTM) | 28.34 |
| EPS (TTM) | 0.56 |
| Earnings Date | May 30, 2024 - Jun 03, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 27.29 |
GlobeNewswireCatalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update
Achieved Total Q1 2024 Revenues of $98.5 Million, a 15.4% YoY Increase, Underscored by Exceptional Execution and Continued Demand for Commercial Products FIRDAPSE® Q1 2024 Net Product Revenues of $66.8 Million, a 16.2% YoY Increase Robust Revenue Momentum for FIRDAPSE® Successfully Commenced the U.S. Launch of AGAMREE® on March 13, 2024 Reported AGAMREE® Q1 2024 Net Product Revenues of $1.2 Million for the First Two Weeks of Commercial Availability Early AGAMREE® Launch Indicators Highlight Prom
ZacksCollegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksCatalyst Pharmaceutical (CPRX) Reports Next Week: Wall Street Expects Earnings Growth
Catalyst (CPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
